The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
Retraction Watch speaks with a researcher who hopes to nudge others away from using problematic cell lines.
Using DNA sequence, gene expression, methylation, and drug response data, researchers saw alterations linked to ovarian cancer subtypes and drug responses.
Genomic analysis uncovered genetic, transcriptional, and drug response shifts between different cultures, or "strains," of the same human cancer cell lines.
Researchers have found genomic, transcriptomic, proteomic, and phenotypic variation in a comparison of HeLa cells across laboratories and over time.
The company has yet to release formal studies, but discussed two cases that illustrate the potential benefit of the methodology in improving patient treatment.
The institute will provide gene editing services and genetically modified cell lines to Analytical Biological Services.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.
The deal covers Atum's custom vectors and Horizon's CHO Source biomanufacturing platform.
Oil made from gene-edited soybeans is already in use, according to the Associated Press.
USA Today reports that Department of Veterans Affairs is teaming up with Sanford Health to provide veterans with genetic testing.
Mother Jones reports there are few regulations overseeing the use of genetic genealogy by law enforcement.
In Science this week: analysis of ancient DNA recovered from Iberian populations, and more.